Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-10-30
1999-10-05
Witz, Jean C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
514 2, 514 21, 424529, 424530, A61K 3514
Patent
active
059626500
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a final drug product comprising coagulation factor VIII in an aqueous solution with a reduced concentration of oxygen. In this way, the factor VIII activity can be retained during storage to a surprisingly high degree. The factor VIII activity can be retained for a prolonged period of time, if the final drug product further comprises an inert gas and/or an antioxidant. The present invention also relates to processes for reducing the oxygen concentration of the aqueous solution, and a method for improving the stability of factor VIII in an aqueous solution by storing the solution under an inert gas atmosphere. By the present invention it is possible to retain at least 50% of the initial activity of factor VIII after storage for at least 6 months at a temperature of 2 to 10.degree. C. and a pH of the solution of 6.5 to 8.5.
BACKGROUND OF THE INVENTION
The stability of proteins is generally a problem in pharmaceutical industry. It has often been solved by drying the protein in various drying processes, such as freeze-drying. The protein has thereafter been distributed and stored in dried form. The solution before drying or freeze-drying, the dried material and the reconstituted product should all be stable, to avoid a substantial loss of activity in the drying process, as well as during storage or handling. The freeze-drying process is a costly and time consuming process step, and it would be of great advantage if this step could be avoided, when preparing a commercial product. Furthermore, the patient necessarily has to reconstitute the dried protein in a solvent before use, which could be inconvenient for the patient.
Haemophilia is an inherited disease which has been known for centuries but it is only within the last three decades that it has been possible to differentiate between the various forms; haemophilia A, haemophilia B and haemophilia C. Haemophilia A is the most frequent form. It affects only males with an incidence of one or two individuals per 10 000 live-born males. The disease is caused by strongly decreased level or absence of biologically active coagulation factor VIII (antihaemophilic factor) which is a protein normally present in plasma. The clinical manifestation of haemophilia A is a strong bleeding tendency and before treatment with factor VIII concentrates was introduced, the mean age of those patients was less than 20 years. Concentrates of factor VIII obtained from plasma have been available for about three decades. This has improved the situation for treatment of haemophilia patients considerably and given them possibility to live a normal life.
Therapeutic factor VIII concentrates have until now been prepared by fractionation of plasma. However, there are now methods available for production of factor VIII in cell culture using recombinant DNA techniques as reported in e.g. J Gitschier et al. Nature 312, p. 330-37, 1984 and EP-A-160 457.
Factor VIII concentrates derived from human plasma contain several fragmented fully active factor VIII forms (Andersson et al, Proc. NatI. Acad. Sci. USA, Vol 83, p. 2979-83, May 1986). The smallest active form has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa held together by a metal ion bridge. Reference is here made to EP-A-1 97 901. corresponds to the 170 kDa plasma factor VIII form in therapeutic factor VIII concentrates. The truncated recombinant factor VIII molecule is termed r-VIII SQ and is produced by Chinese Hamster Ovary (CHO) cells in a cell culture process in serum free medium at finite passage.
The specific activity of r-VIII SQ is about 15 000 IU VIII:C per mg protein.
Recombinant factor VIII SQ is indicated for treatment of classical haemophilia. The dosage is similar to the dosage of the plasma factor VIII concentrates.
The structure and biochemistry of recombinant factor VIII-products in general have been described by Kaufman in Tibtech, Vol 9,1991 and Hematology, 63, p. 155-65, 1991. The structure and biochemistry of r-VIII SQ have been descrbed in WO-A-91/09122.
REFERENCES:
patent: 2896381 (1959-07-01), Lange
patent: 3143471 (1964-08-01), Coady
patent: 4165370 (1979-08-01), Coval
patent: 4597966 (1986-07-01), Zolton et al.
patent: 4709819 (1987-12-01), Lattuada et al.
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 4783441 (1988-11-01), Thurow
patent: 4877608 (1989-10-01), Lee et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5328694 (1994-07-01), Schwinn
Wood et al., Expression of active human factor VIII from combinant DNA clones, Articles, Nature, vol. 312, Nov., 1984, pp. 330-337.
Andersson et al., Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma, Proc. Natl. Acad. Sci., USA, vol. 83, May, 1986, pp. 1979-1983.
Wan et al., CYM of Polysorbates, Journal of Pharmaceutical Sciences, vol. 63, No. 1, Jan., 1974, pp. 136-137.
Shaw, Introduction to Colloid and Surface Chemistry, Liquid-Gas and Liquid-Liquid Interfaces, Butterworths, 1970, pp. 71-73.
Fatouros Angelica
Osterberg Thomas
Pharmacia & Upjohn Aktiebolag
Witz Jean C.
LandOfFree
Oxygen-reduced aqueous solution of factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxygen-reduced aqueous solution of factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxygen-reduced aqueous solution of factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1173008